These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22214461)

  • 41. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?
    Jackaman C; Nelson DJ
    Exp Gerontol; 2014 Jun; 54():53-7. PubMed ID: 24291067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
    Li C; Liu T; Bazhin AV; Yang Y
    J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
    Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
    J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The natural killer cell: a further innate mediator of gouty inflammation?
    Empson VG; McQueen FM; Dalbeth N
    Immunol Cell Biol; 2010 Jan; 88(1):24-31. PubMed ID: 19935769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G; Sternberg C; Ferreira CG
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combinations of Bevacizumab With Cancer Immunotherapy.
    Chen DS; Hurwitz H
    Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mast cell, pro-inflammatory and anti-inflammatory: Jekyll and Hyde, the story continues.
    Conti P; Caraffa Al; Kritas SK; Ronconi G; Lessiani G; Toniato E; Theoharides TC
    J Biol Regul Homeost Agents; 2017; 31(2):263-267. PubMed ID: 28685525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.
    Zhu EF; Gai SA; Opel CF; Kwan BH; Surana R; Mihm MC; Kauke MJ; Moynihan KD; Angelini A; Williams RT; Stephan MT; Kim JS; Yaffe MB; Irvine DJ; Weiner LM; Dranoff G; Wittrup KD
    Cancer Cell; 2015 Apr; 27(4):489-501. PubMed ID: 25873172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pro- and anti-angiogenic agents.
    Bridoux A; Mousa SA; Samama MM
    J Mal Vasc; 2012 Jun; 37(3):132-9. PubMed ID: 22494976
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiangiogenic agents in cancer therapy.
    Lenz HJ
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Innate-Adaptive Immune Crosstalk 2016.
    Shanker A; Thounaojam MC; Mishra MK; Dikov MM
    J Immunol Res; 2017; 2017():3503207. PubMed ID: 28491874
    [No Abstract]   [Full Text] [Related]  

  • 53. Cell mediators of autoimmune hepatitis and their therapeutic implications.
    Montano-Loza AJ; Czaja AJ
    Dig Dis Sci; 2015 Jun; 60(6):1528-42. PubMed ID: 25487192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Innate immunity in cutaneous melanoma.
    Mignogna C; Scali E; Camastra C; Presta I; Zeppa P; Barni T; Donato G; Bottoni U; Di Vito A
    Clin Exp Dermatol; 2017 Apr; 42(3):243-250. PubMed ID: 28052512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
    Kerbel RS; Viloria-Petit A; Klement G; Rak J
    Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tissue-resident and memory properties of human T-cell and NK-cell subsets.
    Lugli E; Hudspeth K; Roberto A; Mavilio D
    Eur J Immunol; 2016 Aug; 46(8):1809-17. PubMed ID: 27431095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune response regulation in the tumor microenvironment by hypoxia.
    Labiano S; Palazon A; Melero I
    Semin Oncol; 2015 Jun; 42(3):378-86. PubMed ID: 25965356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of the anti-tumour immune response by cancer-associated fibroblasts.
    Harper J; Sainson RC
    Semin Cancer Biol; 2014 Apr; 25():69-77. PubMed ID: 24406209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy: Combine and conquer - antiangiogenic immunotherapy.
    Killock D
    Nat Rev Clin Oncol; 2017 Jun; 14(6):327. PubMed ID: 28466876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.